

PRESS RELEASE

Indoco's Q4FY20 Revenues at Rs. 263 Crores

Mumbai, 24th June 2020: Indoco Remedies recorded revenues of ₹ 263 crores during the Fourth quarter of FY 2019-20, as against ₹ 245 crores, same quarter last year. EBIDTA to net sales for the quarter is 12.7 % at ₹ 33.3 crores, compared to 11.7 % at ₹ 28.5 crores, same quarter last year. The Company recorded a net profit of ₹ 5.4 crores, as against ₹ 11.6 crores, same quarter last year.

For the year, the revenues are ₹ 1079 crores as against ₹ 941 crores, last year. EBIDTA to net sales for the year is 11.4 % at ₹ 123.3 crores, compared to 8.1 % at ₹ 76.7 crores, last year. The net profit for the year is ₹ 24.2 crores, as against loss of ₹ 2.8 crores, last year.

The Domestic formulation business grew by 10.3 % for the quarter and by 13.2 % for the year. The International Formulation business achieved a growth of 12.5 % for the quarter and 26.9 % growth, for the year.

Commenting on the 4th quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "The Company's Domestic and International Sales for the quarter got impacted due to supply chain issues and the ban on Paracetamol exports in the month of March'20 due to Covid-19. However, we have adapted to the new normal and are trying to minimize the impact of the pandemic".

For the quarter ended Mar'20, the financials are as under:

(₹ in Crores)

Particulars	Jan'20 - Mar'20	Jan'19 - Mar'19
Net Revenues	263	245
EBIDTA	33.3	28.5
Operating Profit	21.3	17.6
Profit After Tax	5.4	11.6
EPS (Face value ₹ 2/-) (Not annualized)	0.59	1.26

For the year ended Mar'20, the financials are as under:

(₹ in Crores)

Particulars	2019-20	2018-19
Net Revenues	1079	941
EBIDTA	123.3	76.7
Operating Profit	76.0	36.1
Profit After Tax	24.2	(2.8)
EPS (Face value ₹ 2/-)	2.63	(0.31)

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com